Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioDynamics and Holos Life Sciences will together develop non-invasive epigenetic biomarkers associated with sports-related concussions, Oxford said Monday.
Oxford BioDynamics, focused on the epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has appointed new chief financial officer who is expected to join the company by the mid of September 2017.
Oxford BioDynamics, a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has entered into a development agreement with two pharmaceutical companies, that are collaborating on an anti PD-L1 therapy.
Oxford BioDynamics’s subsidiary Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited, to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.
Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on Rheumatoid Arthritis (RA).
Oxford BioDynamics, a biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, has appointed Dr Claudio Carini as an Advisor, effective immediately.
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.